301087 Cofoe Medical Technology
- 37.88
- +0.08+0.21%
Cofoe Medical Technology News
Kefu Healthcare (301087.SZ) announced its 2023 annual results. Net profit of 254 million yuan decreased by 15.71% year-on-year
Kefu Healthcare (301087.SZ) released the 2023 annual performance report. The company achieved operating income of 2 during the reporting period...
Kefu Medical (301087): Self-production rate continues to increase, hearing care helps the company grow
Kefu Healthcare is a leading enterprise in the field of household medical devices. Revenue grew from 851 million yuan in 2017 to 2,977 billion yuan in 2022, with a compound annual growth rate of 28.46%. We think that as the product iterates, it increases
Cinda Securities released a research report on April 10 stating that it gave Corfu Healthcare (301087.SZ) a purchase rating. The main reasons for the rating include: 1) focusing on core categories, the “independent brand+agency” product portfolio, and the
Cinda Securities released a research report on April 10 stating that it gave Corfu Healthcare (301087.SZ) a purchase rating. The main reasons for the rating include: 1) focusing on core categories, the “independent brand+agency” product portfolio, and the five major business lines working hand in hand to drive growth; 2) “online” + “offline” channels go hand in hand to drive growth; 2) the self-production rate continues to increase and enhance profitability. (Mainichi Keizai Shimbun)
Kefu Healthcare (301087.SZ): As of March 29, 2024, the total number of shareholders of the company was about 20,000
Gelonghui, April 3 | Kefu Healthcare (301087.SZ) said on the investor interactive platform that as of March 29, 2024, the total number of shareholders of the company was about 20,000.
Kefu Healthcare (301087.SZ) grants 6.33,000 restricted shares at a grant price of 16.6 yuan/share
Kefu Healthcare (301087.SZ) announced that the company's “2024 Restricted Stock Incentive Plan (Draft)” regulations...
Kefu Healthcare (301087.SZ) plans to grant 6.633 million restricted shares at an award price of 16.6 yuan/share
Kefu Healthcare (301087.SZ) disclosed the 2024 Restricted Stock Incentive Plan (draft), and the company plans to promote...
Express News | Kefu Healthcare: Signed a “Distributed Energy Management Agreement” with Kozo Inkura
Express News | Kefu Healthcare: Plans to repurchase shares for 50 million yuan to 100 million yuan
Express News | 24 companies received fund research, Shanghai Electric Power Co., Ltd. received the most attention
Kefu Medical (301087.SZ): Currently, the Jianer Hearing Testing Center has signed more than 800 contracts
On January 11, Ge Longhui Medical (301087.SZ) said during a survey by institutional investors that at present, Jianer Hearing Testing Center has signed more than 800 contracts, covering 19 provincial markets across the country, including over 100 in Hunan, Sichuan, Guangxi and Hubei. In the next 1-2 years, hearing and hearing will continue to expand at a high rate. We hope to complete the national layout in a short period of time, but the final opening of the store depends on the expansion team, personnel training, etc.
Kefu Medical (301087.SZ): At present, it has achieved independent production of core products such as blood pressure monitors, accounting for about 55% of the revenue
On January 11, Ge Longhui | Kefu Medical (301087.SZ) said during the reception of institutional investors that in 2023, the company promoted product restructuring and new product commissioning work at production bases in Changsha and Xiangyin in an orderly manner, continuously enriching the range of products produced independently and production capacity. At present, the company has achieved independent production of core products such as blood pressure monitors, blood sugar meters, thermometers, wheelchairs, nursing beds, oxygen concentrators, nebulizers, dressings, and masks, accounting for about 55% of the revenue from in-house production. With the increase in the scale of self-production, there is some room for improvement in the company's gross margin, and product quality will continue to improve, providing consumers with higher quality and more
Kefu Healthcare (301087. SZ): Repurchased 2.01% of shares at a total cost of 156 million yuan
Gelonghui (301087.SZ) announced on December 1 | Kefu Healthcare (301087.SZ) announced that as of November 30, 2023, the company has repurchased 4202369 million shares of the company's shares through centralized bidding transactions through special repurchase securities accounts, accounting for 2.01% of the company's total share capital of 209,238,250 shares. The highest transaction price is 39.77 yuan/share, the lowest transaction price is 36.00 yuan/share, and the total transaction amount is 156 million yuan (excluding transaction fees).
Kefu Healthcare (301087): 23Q3 revenue structure optimization, gross margin continues to rise
The incident company released its 2023 three-quarter report. The first three quarters of 2023 achieved operating income of 2.124 billion yuan, an increase of 13.11% over the previous year; realized net profit of 242 million yuan, an increase of 44.47% over the previous year; achieved
Zhang Shaoda, the core technician of Kefu Medical (301087.SZ), resigned and added the certification of Quan Changyun as the core technician
Kefu Medical (301087.SZ) announced that Zhang Shaoda, the company's core technician, resigned from the relevant position due to personal reasons,...
Kefu Healthcare (301087. SZ): Repurchased 2.00% of shares at a cumulative cost of about 156 million yuan
Glonghui on October 31 | Kefu Healthcare (301087.SZ) announced that as of October 31, 2023, the company has repurchased a total of 4184769 million shares of the company's shares through centralized bidding transactions through special securities repurchase accounts, accounting for an increase in the company's total share capital (due to the increase in share capital due to the company's 2021 restricted stock incentive plan, the total number of shares of the company increased from 208,487,500 shares to 209,238,250 shares), with a maximum transaction price of 39.12 yuan/share , the lowest transaction price is 36.
About 1,396,500 restricted shares of Kefu Healthcare (301087.SZ) will be listed and distributed on October 25
Kefu Healthcare (301087.SZ) announced that the number of shareholders applying for the lifting of share sales restrictions this time is 1 (Western...
Kefu Healthcare (301087.SZ): Revenue from rehabilitation aids products increased by 22.54% year-on-year in the first half of the year
Glonghui, October 19丨Kefu Medical (301087.SZ) stated on the investor interaction platform that the company's manual wheelchairs and electric wheelchairs are classified as rehabilitation aids. In the first half of this year, the company's revenue from rehabilitation aids products increased by 22.54% year-on-year. Among them, the sales volume of wheelchair products increased well.
The repurchase ratio of Kefu Medical (301087.SZ) reached 1.89% and cost 146 million yuan
Kefu Healthcare (301087.SZ) announced that up to now, the company has repurchased a total of 3.942,900 shares, accounting for...
Kefu Healthcare (301087): Product Upgrades, Self-Production+Hearing Expansion, and Store Card Slots Drive the Company's Healthy Growth
A leading household medical device company, is in a period of rapid growth. It has been covered for the first time. It has been covered for the first time. Granted a “buy” rating, Kefu Medical has focused on household medical devices for 14 years. After years of deepening channel cultivation and R&D and product expansion, it has formed health monitoring, rehabilitation aids, and respiratory support
Kefu Healthcare (301087): Performance growth is resilient enough to be optimistic about steady growth throughout the year
Event Overview On August 29, 2023, the company released its 2023 interim report. In the first half of 2023, it achieved revenue of 1,519 billion yuan, an increase of 17.23% over the previous year; it achieved net profit of 199 million yuan, a year-on-year increase of 52 million yuan.
Analysis
Price Target
No Data
